Volume 116, Issue 1, Pages 161-167 (January 1999) Chronic blockade of endothelin receptors in cirrhotic rats: Hepatic and hemodynamic effects  Jorge-Luis Poo, Wladimiro Jiménez, Rosa María Muñoz, Marta Bosch-Marcé, Nuria Bordas, Manuel Morales-Ruiz, Manuel Pérez, Ramón Deulofeu, Manuel Solé, Vicente Arroyo, Juan Rodés  Gastroenterology  Volume 116, Issue 1, Pages 161-167 (January 1999) DOI: 10.1016/S0016-5085(99)70240-4 Copyright © 1999 American Gastroenterological Association Terms and Conditions

Fig. 1 Photomicrographs of the liver from a CCl4-treated rat receiving long-term (A) ETA/ETB-receptor antagonist RO 48-5695 or (B) vehicle. Note the marked architectural distortion leading to fully developed cirrhosis (Masson's trichome staining; original magnification 40×). Gastroenterology 1999 116, 161-167DOI: (10.1016/S0016-5085(99)70240-4) Copyright © 1999 American Gastroenterological Association Terms and Conditions

Fig. 1 Photomicrographs of the liver from a CCl4-treated rat receiving long-term (A) ETA/ETB-receptor antagonist RO 48-5695 or (B) vehicle. Note the marked architectural distortion leading to fully developed cirrhosis (Masson's trichome staining; original magnification 40×). Gastroenterology 1999 116, 161-167DOI: (10.1016/S0016-5085(99)70240-4) Copyright © 1999 American Gastroenterological Association Terms and Conditions

Fig. 2 Plasma and hepatic concentrations of ET in control (2) and cirrhotic (▨) rats receiving the ETA/ETB-receptor antagonist RO 48-5695 or vehicle daily for 10 weeks. aP < 0.001, bP < 0.01, cP < 0.05 vs. control rats; dP < 0.05 vs. vehicle. Gastroenterology 1999 116, 161-167DOI: (10.1016/S0016-5085(99)70240-4) Copyright © 1999 American Gastroenterological Association Terms and Conditions

Fig. 2 Plasma and hepatic concentrations of ET in control (2) and cirrhotic (▨) rats receiving the ETA/ETB-receptor antagonist RO 48-5695 or vehicle daily for 10 weeks. aP < 0.001, bP < 0.01, cP < 0.05 vs. control rats; dP < 0.05 vs. vehicle. Gastroenterology 1999 116, 161-167DOI: (10.1016/S0016-5085(99)70240-4) Copyright © 1999 American Gastroenterological Association Terms and Conditions

Fig. 3 Individual values of MAP in basal conditions and 15 minutes after administration of an intravenous bolus of ET-1 (600 pmol/kg body wt) to (A) control and (B) cirrhotic rats treated long-term with RO 48-5695 (▴) or vehicle (•). Gastroenterology 1999 116, 161-167DOI: (10.1016/S0016-5085(99)70240-4) Copyright © 1999 American Gastroenterological Association Terms and Conditions

Fig. 3 Individual values of MAP in basal conditions and 15 minutes after administration of an intravenous bolus of ET-1 (600 pmol/kg body wt) to (A) control and (B) cirrhotic rats treated long-term with RO 48-5695 (▴) or vehicle (•). Gastroenterology 1999 116, 161-167DOI: (10.1016/S0016-5085(99)70240-4) Copyright © 1999 American Gastroenterological Association Terms and Conditions

Fig. 4 Hepatic concentration of hydroxyproline in control (2) and cirrhotic (▨) rats receiving the ETA/ETB-receptor antagonist RO 48-5695 or vehicle daily for 10 weeks. aP < 0.001 vs. control rats; bP < 0.05 vs. cirrhotic rats receiving vehicle. Gastroenterology 1999 116, 161-167DOI: (10.1016/S0016-5085(99)70240-4) Copyright © 1999 American Gastroenterological Association Terms and Conditions

Fig. 5 Representative Northern blot analysis of procollagen type I mRNA in liver tissue of control and cirrhotic rats. Northern blotting was performed with total RNA (15 μg/lane) isolated from the liver. The membrane was probed with an α-32P–labeled 4.1-kb cDNA of human procollagen type I. A picture of the 18S and 28S RNA bands on the formaldehyde/agarose gel is depicted to show equal loading of RNA in all lanes. Gastroenterology 1999 116, 161-167DOI: (10.1016/S0016-5085(99)70240-4) Copyright © 1999 American Gastroenterological Association Terms and Conditions